Genocea biosciences, inc. (GNCA)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
Operating activities
Net Income (Loss) Attributable to Parent

-36,236

-38,950

-29,244

-29,545

-27,488

-27,811

-38,893

-47,928

-58,865

-56,710

-62,012

-57,909

-53,557

-49,573

-43,853

-40,859

-40,150

-42,483

-43,819

-43,219

-40,051

-35,296

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization

0

-

0

0

0

-

0

0

0

-

0

0

0

-

0

0

0

-

0

0

0

-

0

0

0

Stock-based compensation

1,792

1,837

1,843

1,819

1,938

2,153

2,668

3,295

3,857

4,234

4,302

4,328

4,105

4,147

4,137

3,896

3,996

3,848

3,583

3,302

2,939

2,905

0

0

0

Allocation of proceeds to transaction expenses

-

-

-

-

-

2,115

2,115

2,115

2,115

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of warrant liability

-7,554

-986

-9,838

-10,525

-12,153

-14,757

-5,208

-2,315

3,183

0

0

0

0

-

-

-

-

-

-

-

-

725

0

0

0

Net amortization of premium on investments

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

Gain on sale of equipment

42

29

47

47

40

78

72

72

60

22

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash interest expense

451

504

654

393

707

643

579

537

473

502

508

504

493

481

456

427

383

369

463

389

339

254

0

0

0

Asset impairment

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities
Restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Prepaid expenses and other current assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Other non-current assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Accounts payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Accrued expenses and other liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Changes in operating assets and liabilities

0

-

0

0

0

-

0

0

0

-

0

0

0

-

0

0

0

-

0

0

0

-

-

-

-

Net cash used in operating activities

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred rent

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Accrued interest payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Net cash used in operating activities

-

-

-

-

-

-

-

-42,974

-46,073

-47,599

-51,157

-49,978

-46,315

-41,835

-40,090

-38,143

-37,791

-38,360

-36,785

-34,711

-31,818

-27,604

0

0

0

Investing activities
Purchases of property and equipment

1,147

1,135

1,017

721

462

241

143

617

896

1,178

1,818

1,708

2,243

2,538

2,903

3,356

3,129

2,784

2,132

2,311

1,725

1,520

0

0

0

Proceeds from sale of equipment

64

48

57

57

54

110

222

222

206

150

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in investing activities

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from maturities of investments

-

-

-

-

-

-

-

-

-

36,090

56,511

75,144

67,344

79,313

70,389

65,756

61,019

27,498

0

0

0

-

-

-

-

Purchases of investments

-

-

-

-

-

-

-

-

-

153

7,462

7,430

23,918

26,064

49,708

108,438

91,952

89,651

0

0

0

-

-

-

-

Net cash used in investing activities

-

-

-

-

-

-

-

-394

13,850

34,909

47,231

66,006

41,183

50,711

17,778

-46,038

-34,062

-64,937

-44,830

-311

-28,778

-28,573

0

0

0

Financing activities
Proceeds from issuance of common stock, net

55,109

54,669

55,091

55,114

2,920

55,458

0

0

0

-

0

0

0

-

0

0

0

-

0

0

0

-

-

-

-

Finance Lease, Principal Payments

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from equity offerings, net of issuance costs

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Payment of deferred financing costs

-

-

-

-

-

127

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Repayment of long-term debt

0

-

0

0

0

-

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from exercise of stock options

9

21

21

21

12

0

0

255

447

459

520

401

232

227

195

312

364

383

413

649

683

683

0

0

0

Proceeds from the exercise of warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

33

0

0

0

Net cash provided by financing activities

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

-

-

-

-

-

-

-

52,358

49,264

-2,461

-508

932

1,540

1,289

5,902

52,866

52,112

100,498

99,297

52,474

52,228

64,027

0

0

0

Net (decrease) increase in cash, cash equivalents and restricted cash

0

-

0

0

0

-

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net increase (decrease) in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

10,165

-16,410

-31,315

-19,741

-2,799

17,682

17,452

-8,368

7,850

0

0

0

Non-cash financing activities and supplemental cash flow information
Right-of-use asset obtained in exchange for lease liabilities

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash paid in connection with operating lease liabilities

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash paid for interest

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash paid for interest

-

-

-

-

-

-

-

0

0

-

1,234

1,559

1,247

1,255

1,179

775

995

897

894

875

859

815

0

0

0

Conversion of preferred stock to common stock upon closing of IPO

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

81,774

0

0

0

Reclassification of prepaid IPO closing costs from non-current assets to additional paid-in capital

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

997

0

0

0

Reclassification of warrants to additional paid-in capital

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,381

0

0

0

Accretion of redeemable convertible preferred stock to redemption value

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-11

180

0

0

0

Vesting of restricted stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Property and equipment included in accounts payable and accrued expenses

-

-

-

-

-

-

-

-

-

-

-197

187

-312

63

156

419

846

394

0

0

0

-

-

-

-